NutraFuels, Inc. (NTFU) Announces Further Steps for Initiation of Clinical Trials with the Company's Product Line of Oral Spray Nutraceuticals

19:00 EST 22 Feb 2017 | Marketwired

COCONUT CREEK, FL--(Marketwired - February 23, 2017) - NutraFuels, Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced that the company as part of the implementation of initiation of clinical studies on the company's product line of oral spray nutraceuticals has announced the appointment of Kenneth Duchin, Ph.D. as Vice-President Clinical Development and the agreement with Palm Beach Research to conduct clinical studies.

The recent growth of NutraFuels has provided the opportunity to explore the benefits of the oral spray product line. Dr Duchin's career has spanned over 30 years in the pharmaceutical industry in various management positions at Bristol-Myers Squibb and in small and mid-size companies (Theravance, IVAX Corporation, Noven Pharmaceuticals) as well as in start-up virtual organizations. He has extensive drug development experience in a broad range of therapeutic areas, has led several registration programs, authored regulatory NDA and ANDA documents and has led cross-functional development teams. In addition, he has been an inventor of 9 patents and has published nearly 40 papers in peer reviewed journals.

To facilitate the clinical investigations sponsored by Nutrafuels, the company has engaged Palm Beach Research, West Palm Beach FL to conduct the clinical studies. This facility has access to large numbers of patients who routinely participate in clinical trials for many pharmaceutical and biotech companies based in the US and abroad.

"We are very pleased to be working with Ken and Palm Beach Research to initiate clinical trials for our health and wellness products," said Edgar Ward, NutraFuels President/CEO.

Palm Beach Research Center

Since 1994, Palm Beach Research Center has been dedicated to advancing the development of new investigational treatments (drugs, devices) to benefit mankind by assisting pharmaceutical companies in research and eventual FDA approval for public availability. Our experienced research team is designed to streamline efforts to assure maximum efficiency.

Palm Beach Research Center is located in its own building, on the corner of Palm Beach Lakes Boulevard and Okeechobee Boulevard, just west of I-95. The center is almost 7,000 square feet of dedicated research space. There are separate branches for patient recruitment, regulatory, quality assurance, and patient screening in addition to eight full time, clinical research coordinators.

Community support remains outstanding and our database is extensive coming from our unique geographical area, which is comprised of a wide range of age, gender and ethnic backgrounds. These numbers are increasing, as Palm Beach County is one of the fastest growing areas of our country.

Palm Beach Research Center's track record of study enrollment has created a large amount of repeat business. However, Palm Beach Research Center is constantly searching out new partnerships in the quest to work on new medications and treatments seeking FDA approval.

Palm Beach Research is honored to continue a relationship, and form a strategic partnership, with NutraFuels, Inc.

About NutraFuels, Inc.

NTFU was founded in 2010, to manufacture, distribute and market a line of oral spray nutritional dietary products to consumers, retailers and wholesale outlets. Oral spray delivery systems are recognized by many as an effective methodology for delivery of pharmaceutical and nutraceutical products. Oral spray delivery is recognized by consumers for its convenience, dosage precision and timely assimilation into the body. NTFU's product line consists of vitamins and nutrients in an aqueous solution, orally delivered through a non-aerosol pump. NTFU's products are sprayed into the mouth in the form of a fine mist entering the delicate tissue of the mouth. The nutrients are delivered into the bloodstream and assimilated throughout the body more quickly than traditional methods, avoiding the solubility and absorption problems common with most ingested vitamins and nutritional supplements in pill or capsule form.

Safe Harbor

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of NutraFuels, Inc statements relating to goals, plans and projections regarding the NutraFuels' financial position and business strategy. The words or phrases "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think", "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. NutraFuels cautions readers not to place undue reliance on such statements. NutraFuels does not undertake, and NutraFuels specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may differ materially from NutraFuels' expectations and estimates.

NutraFuels, Inc. 6601 Lyons Road, Suite L-6 Coconut Creek, FL 33073 Telephone: 754-227-5692 Email: NEXT ARTICLE

More From BioPortfolio on "NutraFuels, Inc. (NTFU) Announces Further Steps for Initiation of Clinical Trials with the Company's Product Line of Oral Spray Nutraceuticals"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...